Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review Cooper CL; van Heeswijk RPHIV Med 2007[Jan]; 8 (1): 1-7In the context of attempts to simplify treatment regimens and enhance adherence, there is great interest in once-daily dosing regimens for the treatment of HIV-1 infection. Nevirapine has a long half-life and achieves high steady-state plasma concentrations relative to the concentration required to inhibit 50% viral replication in vitro (IC(50)) in patients. For this reason, it has been considered as a once-daily antiretroviral. Pharmacokinetic and efficacy data support the use of this dosing approach, but excess rash and lingering concerns over liver toxicity preclude use of once-daily dosed nevirapine at this time. Tolerance to high nevirapine concentrations may develop when dose escalation is used during initiation of therapy. It is theoretically possible that the benefits of once-daily dosing may be achieved without excess toxicity by switching to once-daily nevirapine following several months of twice-daily administration. This dosing strategy is currently under evaluation.|*Anti-HIV Agents/pharmacokinetics/therapeutic use[MESH]|*Nevirapine/adverse effects/pharmacokinetics/therapeutic use[MESH]|Chemical and Drug Induced Liver Injury[MESH]|Drug Tolerance[MESH]|Exanthema/chemically induced[MESH]|HIV Infections/*drug therapy/virology[MESH]|HIV-1/*drug effects[MESH]|Humans[MESH]|Reverse Transcriptase Inhibitors/pharmacokinetics/therapeutic use[MESH]|Treatment Outcome[MESH] |
